Purpose. Antimicrobial resistance (AMR) profiles of 754 strains of Shigella dysenteriae isolated between 2004 and 2017 from UK travellers reporting symptoms of gastrointestinal (GI) disease were reviewed to look for evidence of emerging AMR associated with travellers' diarrhoea.
INTRODUCTION
Dysentery is characterized by the frequent passage of stools containing blood and mucus, and by severe abdominal pain. The epidemics of bacillary dysentery at the end of the nineteenth century were caused by Shigella dysenteriae serotype 1 [1] . Although S. dysenteriae continues to cause gastrointestinal illness today, epidemics are rare. For the most part, endemic disease is restricted to south Asia and sub-Saharan Africa [2] . In the UK, S. dysenteriae infection is a cause of travellers' diarrhoea.
Of the four Shigella species, S. dysenteriae is the least commonly isolated species in England (S. sonnei, 49 %; S. flexneri, 39 %; S. boydii, 7 %; S. dysenteriae, 4 %) [3] . S. dysenteriae belongs to subgroup A of the genus Shigellae, comprising isolates characterized by the inability to ferment mannitol [4] . Based on somatic O antigens, S. dysenteriae is subdivided into 15 serotypes [5] and two novel serotypes designated E670/74 [National Type Culture Collection (NCTC) #11311] and E117202/96 [6] . Historically, S. boydii and S. dysenteriae were differentiated biochemically by the mannitol test [4] . More recently, molecular typing techniques have demonstrated the close phylogenetic relationship between these two species, within the majority of serotypes of both S. boydii and S. dysenteriae belonging to either clonal complex (CC) 145 or CC288 [3] .
The standard recommended treatment for dysentery is oral rehydration therapy. Antimicrobial chemotherapy may be recommended when the patient is at the extremes of age (infant or elderly), has underlying co-morbidities, or if symptoms are severe and/or prolonged [7] . Surveillance of antimicrobial resistance (AMR) in pathogenic gastrointestinal (GI) bacteria provides an evidence base for empirical treatment protocols [8] . Additionally, AMR testing of GI bacterial pathogens associated with travellers' diarrhoea, including Shigella spp., provides evidence of the global transmission of emerging AMR [9, 10] .
In 2015, Public Health England (PHE) implemented whole genome sequencing (WGS) for the routine public health surveillance of GI pathogens [11] [12] [13] . This has greatly improved our surveillance capabilities with respect to monitoring trends in AMR, as a genome-derived AMR profile is available on every isolate in real-time [14] [15] [16] . The aim of this study was to review the AMR profiles of S. dysenteriae submitted to PHE between 2004 and 2017, to look for evidence of emerging AMR associated with travellers' diarrhoea. As WGS was implemented during the course of this study, we also compared the phenotypic AMR profiles with those derived from WGS data.
METHODS

Bacterial strains
All isolates of S. dysenteriae (n=754) submitted to the Gastrointestinal Bacterial Reference Unit (GBRU) at PHE by local hospital laboratories for confirmation and typing between January 2004 and December 2017 were included in this study. Isolates of S. dysenteriae were from faecal specimens from patients reporting to general practitioners or local hospitals with symptoms of GI disease.
Between 2004 and 2015, traditional phenotypic biochemical and serological tests were used to identify and serotype 704/ 754 isolates of S. dysenteriae. Since 2015, species identification has been performed using the kmer ID approach [3] , and the serotype has been derived from the genome data, for 201/754 isolates of S. dysenteriae (Table S1 , available in the online Supplementray Material). In total, 553/754 isolates were serotyped phenotypically only, 50/754 isolates had their serotype derived from the genome only, and 151/ 754 were typed using both methods. Antimicrobial susceptibility testing results were available for 671/754 isolates. These 671 isolates had either phenotypic (n=470) or genotypic AMR profile results (n=68) or both (n=133).
Speciation and serotyping
Isolates (704/754) were serotyped by the tube agglutination method using in-house antisera raised in rabbits [17] to the somatic lipopolysaccharide O antigens of S. dysenteriae. For identification to the species level, biochemical tests were set up using a combination of appropriate substrates [4] . The ability (or inability) of the bacteria to utilize the substrates was recorded as positive (or negative) results and compared to published tables categorizing the known reactions of Escherichia coli and Shigella species [4, 5] . The differential biochemical tests for S. dysenteriae included a lack of lysine and ornithine decarboxylase activity, indole production and the inability to utilize lactose, mannitol and ortho-Nitrophenyl-b-galactoside. A combination of serology and biochemistry is required to speciate S. dysenteriae.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing (AST) was performed retrospectively on 603 isolates (phenotypic AST only, n=470; phenotypic AST and genome-derived AMR profiles, n=133) recovered from the GBRU archive. MICs for all isolates were determined by agar dilution using Iso-sensitest agar or Mueller-Hinton agar. The antimicrobials tested were ampicillin, chloramphenicol, colistin, sulphonamide, gentamicin, tobramycin, amikacin, streptomycin, tetracycline, trimethoprim, nalidixic acid, ciprofloxacin, ceftazidime, cefotaxime, cefoxitin, cefpirome, ertapenem and temocillin. Breakpoints used for interpretation were as recommended by EUCAST and the EU Reference Laboratory Antimicrobial Resistance recommended screening guidance (www.crl-ar.eu/201-resources.htm#cutoff). Temocillin and cefoxitin were included in the panel to aid detection of OXA-48-like carbapenemases and AmpC production, respectively.
Whole genome sequencing
For 201/754 isolates (Table S1 ), genomic DNA was extracted, fragmented and tagged for multiplexing with Nextera XT DNA Sample Preparation Kits, followed by paired-end sequencing on an Illumina HiSeq platform to produce 80-100 bp short-read sequence fragments (Illumina, Cambridge, UK). FASTQ reads from all sequences in this study can be found at the PHE Pathogens BioProject at the National Center for Biotechnology Information (PRJNA315192) and the SRR accessions are listed in Table S1 .
Serotypes of S. dysenteriae were determined by a single O-antigen, encoded by different wzx and wzy gene sequences. These genes and their respective O-antigen gene clusters for S. dysenteriae serotypes 1-13 have been sequenced [18] and deposited in online nucleotide sequence databases (Table 1) , allowing them to be used as a resource for in silico genomic serotyping of isolates. Sequences from the S. dysenteriae type strains in the GBRU archive were used to identify serotypes 14, 15 and the novel serotype E112707/96 (Table 1) . Using the GeneFinder tool, FASTQ reads were mapped to the O-antigen wzx and wzy gene sequences using Bowtie 2 [19] and the best match to each target was reported with metrics, including coverage, depth and nucleotide similarity in XML format for quality assessment. For in silico predictions of serotype, only results that matched to a gene determinant at >80 % nucleotide identity over >80 % target gene length were accepted.
Reference sequences for acquired resistance genes and resistance-conferring mutations relevant to b-lactams (including carbapenems), fluoroquinolones, aminoglycosides, chloramphenicol, macrolides, sulphonamides, tetracyclines, trimethoprim, rifamycins and fosfomycin, were curated from those described in the Comprehensive Antimicrobial Resistance Database 1.1.4 (http://arpcard.mcmaster.ca) and the Resfinder 17-Feb-2017 datasets (https://cge.cbs.dtu.dk/ services/data.php) by removing duplicate sequences that were identified by BLAST. Chromosomal mutations focused on variations in the QRDRs of gyrA, gyrB, parC and parE, which are associated with resistance to quinolones, and also in rpoB for rifampicin resistance. Using the GeneFinder tool, FASTQ reads were mapped to AMR determinants using Bowtie 2 [19] and the best match to each target was reported with metrics, including coverage, depth, mixture and nucleotide similarity in XML format for quality assessment. The data was parsed line-by-line to determine the base calls at each nucleotide position with filtering based on read depth (>5 reads per base) and base-call agreement (>85 %). The presence of genes was defined based on 100 % read coverage and >90 % nucleotide identity relative to the reference sequence with the exception of b-lactamase variants, which were determined with 100 % identity using the reference sequences downloaded from the Lahey (www. lahey.org) and NCBI b-lactamase data resources (www. ncbi.nlm.nih.gov/pathogens/beta-lactamase-dataresources).
Statistical analysis
Comparisons were made between the AMR profiles associated with cases who reported travel to Africa and Asia in the 7 days prior to onset of symptoms. Fisher's exact test was used to assess statistical significance. A P-value of <=0.05 was deemed statistically significant. All statistical analyses were performed using STATA 12.0 (Stata Corporation).
RESULTS
Epidemiological analysis
Between 2004 and 2017, the average number of isolates of S. dysenteriae submitted to GBRU each year was 54, peaking at 82 in 2010 and declining to 26 in 2017 (Fig. 1 ). Of the 754 cases infected with S. dysenteriae, 49.5 % (373/754) were female, 47.7 % (360/754) were male and gender was not stated for 1.5 % (11/754) of cases. There were 581 (77.0 %) adults (>16 years old), 113 (15.0 %) children (16 years old or younger) and the date of birth was not provided for 60 (8 %) cases. A travel history was provided for 72.7 % (548/ 754) of cases, of which 90.9 % (498/548) reported travel within 7 days of onset of symptoms [91.8 % (457/498) reported travel to either Asia or Africa] and 9.1 % (50/498) reported no travel in that time frame. The top four travel destinations reported were India (n=130), Pakistan (n=87), Egypt (n=73) and Afghanistan (n=36); the latter was mostly reported by British military personnel [20] . No travel history was provided by 27.3 % (206/754) of cases.
Serotyping data
Over the course of the study, the serotypes identified were 1 (n=10), 2 (n=217), 3 (n=108), 4 (n=57), 6 (n=8), 7 (n=3), 8 (n=3), 9 (n=52), 10 (n=1), 11 (n=1), 12 (n=35), 13 (n=15), 14 (n=12), E112707/96 (n=150) and O-unidentifiable (n=82) ( Table 2 ). Serotypes 1, 2, 6, 9, 11, 12 and 13 were more common in cases reporting travel to Asia and serotypes 3, 4, 7, 8 and 14 were more common in cases reporting shown instead is the accession for the E. coli O130 wzy gene from the same study, which has a highly similar sequence (97 % identity).
travel to Africa, although 10/13 detected serotypes were isolated from travellers to both continents (Table 2) .
Phenotypic serotypes and WGS-derived serotypes were compared for 151 isolates, of which 137 isolates had concordant results (Table S1 ). Fourteen isolates were O-unidentifiable by phenotypic serotyping but were serotyped using WGS data (serotype 2, n=13; serotype 3, n=1). Eight isolates were designated O-unidentifiable using both methods.
Comparison between phenotypic and genotypic AMR The phenotypic and genotypic AMR results correlated well, with 121 (90.1 %) of 133 isolates having concordant results across their complete susceptibility profile, which included 10 classes of antimicrobials. Each isolate exhibiting a discrepancy had one mismatch; therefore there were 12 (0.9 %) discordant results out of a possible 1330 isolate/antimicrobial class combinations. All 12 discordant results were associated with streptomycin resistance. Four isolates were predicted to be resistant from the genome-derived AMR data (harbouring strA-strB) but were phenotypically susceptible (MICs 4 mg/L), and eight were predicted to be susceptible from the genome data but were phenotypically resistant (MICs 16-32 mg/L). Currently, the breakpoint used at PHE for determining streptomycin resistance is 8 mg/L.
Resistance to b-lactams
Of the 671 isolates in this study that had AMR profiles (either derived from AST or WGS data or both), 363 (54.1 %) were resistant to ampicillin. Of the 201 isolates with WGS-derived AMR profiles, 145 (72.1 %) had genes predicted to confer resistance to ampicillin (Table 3) .
Specifically, the genes detected encoded the penicillinases bla TEM-1 (n=50), bla TEM-117 (n=7), bla TEM-191 1 (n=6), bla OXA-1 (n=61), bla OXA-4 (n=1), bla OXA-33 (n=1), bla OXA-129 (n=2), the extended spectrum beta-lactamase (ESBL) bla CTX-M-15 (n=18), and the AmpC gene bla CMY-4 (n=2). bla TEM-1 was more commonly reported in cases reporting travel to Asia (19/81, 23.5 %) than Africa (7/42, 16.7 %) although the association was not significant (P=0.487), whereas bla OXA-1 was significantly associated with cases reporting travel to Africa (n=19/42, 45.2 %) compared to those reporting travel to Asia (n=17/81, 21.0 %) (P=0.007) ( Table 3) . Of the 18 isolates with bla CTX-M-15 , 10 were from cases reporting travel to Afghanistan (n=4), Pakistan (n=2), Bangladesh, Iraq, Turkey and United Arab Emirates, three reported no recent travel and a travel history was unavailable for five cases (Table 3) . Carbapenemases were not detected in any of the isolates in this study (n=671) by AST or genome-derived AMR analysis.
Resistance to quinolones
Overall, 200/671 (57.7 %) isolates exhibited reduced susceptibility (MIC >0.064<0.5 mg/L) to ciprofloxacin. Of these, 113/201 had genotypic AMR profiles associated with conferring reduced susceptibility to ciprofloxacin; 44 (38.9 %) had a single gyrA mutation, either S83L (n=34), S83A (n=1), D87Y (n=7) or D87G (n=2), and 61 (54.0 %) harboured the plasmid-mediated quinolone resistance (PMQR) determinant, qnrS1 without quinolone resistance determining regions (QRDR) mutations. An additional eight (7.1 %) isolates had qnrS1 in combination with a single gyrA mutation, either S83L (n=1) or D87Y (n=7) ( Table 2 ). The presence of qnrS1 in combination with a single gyrA mutation did not increase the MIC to ciprofloxacin, which remained >0.064<0.5 mg/L. Reduced susceptibility to ciprofloxacin was significantly associated with cases reporting travel to Asia (63/81, 77.8 %) compared to those reporting travel to Africa (6/42, 14.3 %) (P<0.001) ( Table 3 ).
Resistance to aminoglycosides
There were 418/671 (62.3 %) isolates resistant to streptomycin, and 163/201 (81.1 %) isolates had genes predicted to confer streptomycin resistance. In total, 146 of the 201 sequenced isolates (72.6 %) had strA-strB, of which 121/ 201 (60.2 %) had strA-strB only and 26/201 (12.9 %) strAstrB and an aadA variant (aadA1b, n=16; aadA5, n=10) ( Table 2 ). There were 16/201 (8.0 %) isolates that had aadA1b only. None had genes expected to confer resistance to a broad range of aminoglycosides, and there were no 16S rRNA methyltransferase genes detected. strA-strB and aadA1b were isolated from cases reporting travel to both Asia (n=56/81, 69.1 % and n=13/81, 16.0 % respectively) and Africa (n=32/42, 76.2 % and 9/42, 21.4 %) but aadA5 was associated with travel to Asia only (n=9, 11.1 %) (Table 3) . Overall, there was no significant difference in the prevalence of isolates exhibiting resistance to streptomycin from cases travelling to Africa or Asia (P=0.105).
Resistance to trimethoprim, tetracyclines, phenicols and sulphonamides Of the 671 isolates with an AMR profile, 534 (80.0 %), 323 (48.1 %), 226 (33.7 %) 510 (76.0 %) were resistant to trimethoprim, tetracycline, chloramphenicol and the sulphonamides, respectively. Of the 201 isolates with genome-derived AMR profiles, 175 (87.0 %) had one or more dfrA genes (dfrA1=106; dfrA7=7; dfrA14=65; dfrA17=10; dfrA21=2), conferring resistance to trimethoprim (Table 2 ). There were 15 isolates with two different dfrA genes (dfrA1-dfrA14 n=8, dfrA1-dfrA17, n=3; dfrA7-dfr14, n=1; dfrA14-dfrA17, n=3). Overall, 141 (72.1 %) isolates had tet(A) ( Table 2) ; no other tetracycline resistance determinants were detected. In total, 152 (75.2 %) isolates had genes predicted to confer sulphonamide resistance; 140 (69.1 %) had sul2 and 12 (6.0 %) had both sul1 and sul2 (Table 2 and S1). Overall, there was no significant difference in the prevalence of isolates exhibiting resistance to trimethoprim (P=1.000), tetracycline (P=0.835) and sulphonamides (P=0.307) (Table 3) .
Altogether, 66 isolates (32.7 %) had catA1, predicted to confer chloramphenicol resistance (Table 2) . catA1 was significantly associated with cases reporting travel to Africa (n=18/42, 42.9 %) compared to those reporting travel to Asia (n=19/81, 23.4 %) (P=0.038) ( Table 3) .
Resistance to macrolide, rifamycins and fosfomycin None of the isolates was predicted to be resistant to the macrolides, rifamycins and fosfomycin
Multidrug-resistant AMR profiles and general trends
Of the 671 isolates in this study that had AMR profiles, 621 were resistant to at least one antimicrobial on the panel tested, and 534 (86.8 %) were multidrug resistant (MDR) (resistant to three or more classes of antimicrobials). The most common genotypic resistance profiles Table 2 . S. dysenteriae serotypes identified in all isolates (n=754) and in those specifically reporting travel to Africa (n=172) and Asia (n=285)
The remaining cases either reported no recent (within 7 days of onset of symptoms) travel (n=40), travel to destinations other than Africa or Asia (n=17), recent travel but destination not reported (n=19) or no travel history data was available (n=223) (see Table S1 ).
Serotype Total no. (%) n=754
No. associated with cases reporting travel to Africa (%) n=172
No. associated with cases reporting travel to Asia (%) n=285 were: (i) bla TEM-1 , strA-strB, qnrS1, dfrA14 and sul2 with or without tet(A) (n=77, 22.6 %) and (ii) bla OXA-1 1, strAstrB, dfrA1, tet(A), sul2 and cat-1 with or without gyrA S83L (n=38, 11.1 %).
Throughout the course of the study, resistance to all classes of antimicrobials (except the phenicols) increased, with the greatest increase seen in isolates exhibiting reduced susceptibility to ciprofloxacin; 3.8 % in 2004 to 75.7 % in 2017 (Fig. 2) . Overall, 20 (3.0 %) isolates harbouring either bla CTX-M-15 or bla CMY-4 have been detected since 2012.
DISCUSSION
Throughout the period of this study, the numbers of S. dysenteriae isolated from returning travellers were low compared to the other Shigella species [3] . The Global Enteric Multicenter Study (GEMS) on the burden and aetiology of diarrheal illness in children over 3 years at sites in subSaharan Africa and South Asia, also found S. dysenteriae had the lowest incidence of all four Shigella species (S. flexneri 65.9 % and S. sonnei 23.7 %, S. boydii 5.4 %, S. dysenteriae 5.0 %) [2] . During our study, there was a reduction in the number of cases of S. dysenteriae from 2012 to the Table 3 . Resistance genes identified in S. dysenteriae, the predicted resistance phenotype and their prevalence in all sequenced isolates (n=201) and in those specifically reporting travel to Africa (n=42) and Asia (n=81)
The remaining cases either reported no recent (within 7 days of onset of symptoms) travel (n=21), recent travel but destination not reported (n=9) or no travel history data was available (n=48) (see Table S1 ). present date. Between 72 and 90 % of isolates of S. dysenteriae submitted to GBRU are from returning travellers, and the decrease in numbers may be caused by a reduction in the number of UK residents travelling to regions where S. dysenteriae is endemic. However, countries in endemic regions have also reported decreases in the incidence of S. dysenteriae during this time frame [21] [22] [23] [24] [25] . S. dysenteriae was the prevalent Shigella species in Nepal in the years prior to 2005 but has since been replaced by S. flexneri [21] . Decreasing rates of S. dysenteriae have also been observed on the Indian sub-continent [22] [23] [24] [25] .
In Kenya, most Shigella isolates were S. flexneri (64 %) followed by S. dysenteriae (11 %); six of the 27 isolates of S. dysenteriae in this study were serotype 1 [26] . Serotype 1, the cause of prolonged pandemics of dysentery throughout the twentieth century [1] , has not been isolated from UK travellers since 2007, nor was it isolated during the GEMS study [2] . In India and Bangladesh, the incidence of S. dysenteriae serotype 1 has steadily declined since 2002 [6, 27] .
Other S. dysenteriae serotypes have rarely been involved in outbreaks or epidemics, with the exception of a strain of S. dysenteriae serotype 2 that caused an outbreak in Bangladesh between 1999 and 2002 [28] . The more common serotypes identified in the GEMS study, specifically serotypes 2 (n=17), 3 (n=10), 4 (n=12), 8 (n=1), 9 (n=1) and 12 (n=5) [2] , were also the most commonly detected serotypes identified in our study with the exception of the novel serotype E112707/96 [2] , the second most commonly isolated serotype in our study. The implementation of WGS has reduced the numbers of isolates S. dysenteriae that were designated O-unidentifiable by phenotypic serotyping. Failure to phenotypically serotype Shigella species may be due to antisera failing quality control procedures, unresolvable cross reactions, dysfunctional O antigens encoding genes or novel serogroups [29] .
There was good correlation between phenotypic AST and genome-derived AMR profiles. All 12 mismatches were associated with streptomycin resistance. Tyson et al. [30] reported that the majority of discordant results in their study were associated with streptomycin and were mostly attributable to the inability to detect evidence of phenotypic resistance, despite the isolates having intact streptomycin resistance coding regions and promoters [30] . We previously reported isolates of S. sonnei and enteroaggregative E. coli harbouring strA-strB that were phenotypically susceptible to streptomycin, with MICs just below the breakpoint (8 mg/L) [14, 15] . Tyson et al. [30] proposed the presence of these genes should be used as an indicator of resistance potential and this may present a reasonable alternative to conventional phenotypic testing [30] .
Antimicrobial resistance in the genus Shigella is more common than in any other enteric bacteria [14, 16, 25, 31] . High level of resistance among S. dysenteriae to the first-line drugs commonly used in the treatment of shigellosis, including ampicillin, chloramphenicol and cotrimoxazole, has been reported from various studies worldwide [24, [32] [33] [34] and was observed throughout this study from 2004 to 2017. Over the past decade, S. dysenteriae have become increasingly resistant to most widely used antimicrobials [20, [35] [36] [37] . Since the late 1990s, the fluoroquinolones, including ciprofloxacin, norfloxacin and ofloxacin, have been the drug of choice for all the patients with shigellosis, irrespective of their ages [38] [39] [40] . The emergence of the ciprofloxacin resistance from southeast Asia is well documented and is further evidenced in this study [35] [36] [37] [38] [39] [40] [41] .
Increasing resistance to the fluoroquinolones has led to the use of ciprofloxacin alternatives, including ceftriaxone and azithromycin. Unlike other species of Shigella in the GBRU archive [11, 12, 15] , no resistance to azithromycin was detected in S. dysenteriae during this study, although cephalosporin resistance has been detected every year since 2014. Globally, ESBLs are on the rise in Shigella [42, 43] . Ceftriaxone has been used as a reserved antibiotic for treatment of MDR shigellosis, and this emerging ceftriaxone resistance has limited the options for therapy [44] .
Increasing MDR, along with increasing levels of reduced susceptibility to the fluoroquinolones (3.8 % in 2004 to 75.7 % in 2017) and the third generation cephalosporins (20 isolates harbouring either bla CTX-M-15 or bla CMY-4 have been detected since 2012), in Shigella dysenteriae causing travellers' diarrhoea is a cause for concern, and provides further evidence for the need for restricted use of antimicrobial agents and continuous monitoring. The implementation of WGS at PHE has improved our capability to monitor the emergence of AMR in GI bacterial pathogens. These AMR surveillance data contribute to an integrated disease surveillance system that informs policy at the local level and facilitates the tracking of AMR transmission on a global scale. 
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